Slide 1: 2nd Quarter Fiscal 2026 Earnings Presentation
2nd Quarter Fiscal 2026 Earnings Presentation February 5, 2026 | We shop. You save.
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use o
Slide 3: 2Q Earnings Highlights
2Q Earnings Highlights • Consolidated ◦ Solid revenue growth of 12% year-over-year, driven by a strong Senior AEP and continued Healthcare Services growth ◦ New $415 million credit facility enhances operational flexibility and extends maturities to 2031 • Senior ◦ Successful AEP drove 2% Senior reve
Slide 4: Another Strong AEP Season for Senior
Another Strong AEP Season for Senior MA Policies Agent Productivity† 000s 257k 33% 235k 248k 12% 2Q24 2Q25 2Q26 2Q24 2Q25 2Q26 Adjusted EBITDA* Margins Marketing Expense Per Policy**† 39% 39% 22% 20% 32% 2Q24 2Q25 2Q26 2Q24 2Q25 2Q26 *See "Non-GAAP Financial Measures" section on slide 2 **Represents
Slide 5: High-Touch Model Again Provided Retention Stability
High-Touch Model Again Provided Retention Stability Despite significant carrier plan disruption again this year, our proactive, high-touch approach helped tens of thousands of seniors understand their benefit changes and achieved strong terminated plan customer recapture. Pre-2025 2025 AEP Carrier 2
Slide 6: SelectRx Addresses Critical Senior Health & Cost Issues
SelectRx Addresses Critical Senior Health & Cost Issues Industry Problem Solution Our pharmacists specialize in working with multiple ~60% of seniors take medications prescribed prescribing physicians and pharmacies to bring by 4 or more physicians one cohesive pharmacy solution 47% of seniors takin
Slide 7: Improved Capital Flexibility and Term Loan Maturity
Improved Capital Flexibility and Term Loan Maturity Legacy Credit Facility* $261M January 2026: Term Debt Refinance $54M • New $415M credit facility provides sufficient growth CY'26 CY’27 CY’28 CY’29 CY’30 CY’31 capital for foreseeable future • $325M term loan and New Credit Facility revolving credi
Slide 8: Consolidated Financial Summary
Consolidated Financial Summary Commentary Revenue Adjusted EBITDA* $MM $MM • Robust revenue growth driven by continued strength in Healthcare $537 Services and strong Senior AEP $481 results $88 $85 • Adjusted EBITDA* of $85 million decreased slightly year-over-year due to PBM reimbursement headwind
Slide 9: Senior Financial Summary
Senior Financial Summary Commentary Revenue Adjusted EBITDA* $MM $MM 39% 39% • Senior revenue grew 2% year- $262 $256 over-year on 4% higher approved policy volume $101 $102 • Adjusted EBITDA* increased modestly year-over-year to $102 million • Near record high 39% Adjusted EBITDA* margins, in line
Slide 10: Healthcare Services KPIs
Healthcare Services KPIs SELECTRX Members Revenue & Adjusted EBITDA* 120 113 $MM 108 107 106 100 97 $214 $221 $231 80 $190 $183 60 2Q25 3Q25 4Q25 1Q26 2Q26 40 20 $12 $6 $7 $2 $1 0 2Q25 3Q25 4Q25 1Q26 2Q26 REVENUE ADJUSTED EBITDA* *See "Non-GAAP Financial Measures" section on slide 2 | We shop. You s
Slide 11: Life Financial Summary
Life Financial Summary Commentary Revenue Adjusted EBITDA* $MM $MM • Revenue increased 9% year-over- $44 year driven by continued Final $40 Expense premium growth, which increased 24% year-over-year • Final Expense continues to $7 execute well and deliver attractive returns and cash flow $6 • Term L
Slide 12: Capital Structure Transformation
Capital Structure Transformation October 2024: Initial Securitization ✓ February 2025: Preferred Equity ✓ January 2026: Term Debt Refinance ✓ • Completed $100M securitization • Announced $350M strategic investment • New $415M credit facility provides sufficient growth capital for foreseeable • Estab
Slide 13: Revised FY26 Financial Guidance
Revised FY26 Financial Guidance REVENUE $1.61B to $1.71B from $1.65 billion to $1.75 billion ADJUSTED EBITDA* $90M to $100M from $120 million to $150 million* *See "Non-GAAP Financial Measures" above on slide 2. | We shop. You save. 13
Slide 14: Continued Focus on Driving Meaningful Cashflow
Continued Focus on Driving Meaningful Cashflow Commentary Cash EBITDA* Operating Cash Flow $MM $MM $60 - $70 $25 - $35 $54 • Forecasting FY26 Cash EBITDA* of $60-70 million representing ~20% growth year-over-year at the mid-point • Operating Cash Flow of $25-35 million expected in FY26 driven by sol
Slide 15: Supplemental Information
Supplemental Information | We shop. You save. 15
Slide 16: Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense
Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense (benefit) 2Q FY 2026 Healthcare (in thousands) Senior Services Life Total Total revenue from reportable segments $ 261,539 $ 230,654 $ 43,623 $ 535,816 Less: Cost of commissions and other services revenue (74,391) (8,35
Slide 17: Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense
Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense (benefit) 2Q FY 2025 Healthcare (in thousands) Senior Services Life Total Total revenue from reportable segments $ 255,578 $ 183,370 $ 39,861 $ 478,809 Less: Cost of commissions and other services revenue (75,042) (7,93
Slide 18: Reconciliation of Non-GAAP Measure
Reconciliation of Non-GAAP Measure Reconciliation of Net Income to Adjusted EBITDA 2Q FY FY YTD (in thousands) 2026 2025 2026 2025 Net income $ 69,293 $ 53,236 $ 38,834 $ 8,690 Share-based compensation expense 3,475 4,699 7,802 8,545 Transaction costs 662 6,719 846 7,544 Depreciation and amortizatio
Slide 19: Net Income to Cash EBITDA Reconciliation
Net Income to Cash EBITDA Reconciliation Forecasted FY26 (in thousands) Consolidated Net income1 $ 30,878 Income tax expense 8,464 Interest expense, net 44,420 Change in fair value of warrants1 (34,332) Impairment of equity-method investment 1,000 Depreciation and amortization 17,877 Transaction cos
Slide 20: Net Income to Cash EBITDA Reconciliation
Net Income to Cash EBITDA Reconciliation FY25 (in thousands) Consolidated Net income $ 47,580 Income tax expense 931 Interest expense, net 79,385 Change in fair value of warrants (59,525) Impairment of long-lived assets 4,209 Loss on disposal of property, equipment, and software 240 Depreciation and
Slide 21: SelectQuote Inc.
SelectQuote Inc. 6800 West 115th Street Suite 2511 Overland Park, Kansas 66211 Phone: (877) 678-4086 Investor Relations investorrelations@selectquote.com | We shop. You save. 21